Economic Evaluation of Smoking-Cessation Therapies

BackgroundSmoking is probably the most important among preventable health risks. Health economic evaluation of smoking-cessation interventions, applying a lifetime perspective, is made possible by available epidemiological knowledge. The well established method of performing cost-effectiveness analyses of smoking-cessation interventions involves mathematical modelling (both deterministic and stochastic) of future events important for cost effectiveness.ObjectivesThis study surveys cost-effectiveness analyses of smoking cessation, with a particular focus on the mathematical modelling and simulation analyses performed.Data SourcesA systematic literature search was performed using the databases MEDLINE, Econlit and Academic Search Complete.Study SelectionHealth economic evaluations, published as full-length journal articles, were searched for.Results423 studies were identified and 78 were finally included, of which 30 were assessed as being highly relevant, based on the application of simulation modelling.ConclusionsIn general, studies are well performed as regards modelling. Common weaknesses include reporting of modelling details; validation of used simulation models; and the handling of structural uncertainty and different types of heterogeneity.

[1]  W. Groot,et al.  Systematic Review of Economic Evaluations of Smoking Cessation: Standardizing the Cost-Effectiveness , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[2]  F. Paccaud,et al.  Cost-effectiveness analysis of the first-line therapies for nicotine dependence , 2003, European Journal of Clinical Pharmacology.

[3]  R. Hoogenveen,et al.  Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[4]  T. Cooper.  Department of Health, Education, and Welfare. , 1976, Military medicine.

[5]  J. Hughes.  How confident should we be that smoking cessation treatments work? , 2009, Addiction.

[6]  S. Chick,et al.  A taxonomy of model structures for economic evaluation of health technologies. , 2006, Health economics.

[7]  Rudolf T Hoogenveen,et al.  Chronic disease projections in heterogeneous ageing populations: approximating multi-state models of joint distributions by modelling marginal distributions. , 2010, Mathematical medicine and biology : a journal of the IMA.

[8]  K. Fagerström,et al.  The epidemiology of smoking: health consequences and benefits of cessation. , 2002, Drugs.

[9]  R. Hoogenveen,et al.  If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands. , 2010, Addiction.

[10]  David O. Meltzer,et al.  Accounting for future costs in medical cost-effectiveness analysis. , 1997 .

[11]  E. C. Hammond,et al.  Smoking and death rates: report on forty-four months of follow-up of 187,783 men. 2. Death rates by cause. , 1958, Journal of the American Medical Association.

[12]  P M Barton,et al.  The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. , 2002, Health technology assessment.

[13]  H. Brønnum-Hansen,et al.  How good is the Prevent model for estimating the health benefits of prevention? , 1999, Journal of epidemiology and community health.

[14]  J. Matthews,et al.  Cost-effectiveness of the Australian National Tobacco Campaign , 2008, Tobacco Control.

[15]  B. Lindgren,et al.  Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003. , 2008, Respiratory medicine.

[16]  D. Horn.  Smoking and health: A report of the royal college of physicians on smoking in relation to cancer of the lung and other diseases , 1962 .

[17]  Abdullahi O. Abdulkadri,et al.  Cost-Effectiveness Analysis of the Not On Tobacco Program for Adolescent Smoking Cessation , 2008, Prevention Science.

[18]  Richard Doll,et al.  The Mortality of Doctors in Relation to Their Smoking Habits , 1954, British medical journal.

[19]  E. Krall,et al.  Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study. , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[20]  R. Guymer,et al.  Cost-effectiveness of smoking cessation to prevent age-related macular degeneration. , 2008, Cost effectiveness and resource allocation : C/E.

[21]  G. Guindon,et al.  Tobacco control country profiles , 2003 .

[22]  J. Matthews,et al.  The Quit Benefits Model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking , 2007, Cost effectiveness and resource allocation : C/E.

[23]  P. Franks,et al.  Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. , 1996, JAMA.

[24]  F. Song,et al.  Cost-Effectiveness of Pharmacological Interventions for Smoking Cessation: A Literature Review and a Decision Analytic Analysis , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[25]  M. Thun,et al.  Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. , 2000, JAMA.

[26]  K. Bolin,et al.  Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence. , 2008, Journal of evaluation in clinical practice.

[27]  J. W. Gardner,et al.  Health, Education, and Welfare. , 1965, Science.

[28]  K. Nackaerts,et al.  Cost Effectiveness of Varenicline in Belgium, Compared with Bupropion, Nicotine Replacement Therapy, Brief Counselling and Unaided Smoking Cessation , 2009, Clinical drug investigation.

[29]  Stephen S. Lim,et al.  Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia , 2007, Tobacco Control.

[30]  R. Doll,et al.  Lung Cancer and Other Causes of Death in Relation to Smoking , 1956, British medical journal.

[31]  C. Knight,et al.  Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. , 2008, PharmacoEconomics.

[32]  Martine Hoogendoorn,et al.  Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands , 2008, Current medical research and opinion.

[33]  Tammy O. Tengs,et al.  The cost-effectiveness of intensive national school-based anti-tobacco education: results from the tobacco policy model. , 2001, Preventive medicine.

[34]  S. Golder,et al.  Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment , 2012, PharmacoEconomics.

[35]  E. de Nigris,et al.  Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries. , 2009, European journal of public health.

[36]  H Schultz,et al.  Tobacco or health: A global status report. , 1998, Annals of Saudi medicine.

[37]  P. Tillgren,et al.  A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children , 2005, Scandinavian journal of public health.

[38]  M. Halpern,et al.  Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[39]  L. Gunning-Schepers,et al.  The health benefits of prevention: a simulation approach. , 1988, Health policy.

[40]  K. Olsen,et al.  Cost-effectiveness of the Danish smoking cessation interventions , 2006, The European Journal of Health Economics.

[41]  J. Cairns,et al.  Cost effectiveness of a mass media-led anti-smoking campaign in Scotland. , 1997, Tobacco control.

[42]  E. C. Hammond,et al.  SMOKING AND DEATH RATES—REPORT ON FORTY-FOUR MONTHS OF FOLLOW-UP OF 187,783 MEN: I. TOTAL MORTALITY , 1958 .

[43]  E. Lee,et al.  Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[44]  M. Sculpher,et al.  Decision Modelling for Health Economic Evaluation , 2006 .

[45]  Should the consumption of survivors be included as a cost in cost-utility analysis? , 2004, Health economics.

[46]  H. Sintonen,et al.  Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers , 2010, Current medical research and opinion.

[47]  P. Ernst.  Long acting beta 2 agonists and the risk of life threatening asthma. , 1998, Thorax.

[48]  B. Lindgren,et al.  The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. , 2006, Chest.

[49]  E. C. Hammond,et al.  Smoking and death rates; report on forty-four months of follow-up of 187,783 men. I. Total mortality. , 1958, Journal of the American Medical Association.

[50]  F. Paccaud,et al.  Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison , 2006, Tobacco Control.

[51]  C. Knight,et al.  The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[52]  Sajjad Ahmad,et al.  Federal policy mandating safer cigarettes: a hypothetical simulation of the anticipated population health gains or losses. , 2004, Journal of policy analysis and management : [the journal of the Association for Public Policy Analysis and Management].

[53]  D. Wetter,et al.  Late relapse/sustained abstinence among former smokers: a longitudinal study. , 2004, Preventive medicine.

[54]  C. Godfrey,et al.  Development of the health and economic consequences of smoking interactive model , 2001, Tobacco control.

[55]  G. Keating,et al.  Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation. , 2010, PharmacoEconomics.

[56]  M. Raw,et al.  Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority. , 1998, Thorax.

[57]  M. Rutten-van Mölken,et al.  Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[58]  J. Nyman.  More on survival consumption costs in cost-utility analysis , 2006 .

[59]  A. Elixhauser.  The Costs of Smoking and the Cost Effectiveness of Smoking-Cessation Programs , 1990, Journal of public health policy.

[60]  Nicky J Welton,et al.  A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. , 2008, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[61]  J. Ramsberg,et al.  On survival consumption costs: a reply to Nyman. , 2008, Health economics.

[62]  E. A. Graham,et al.  Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases. , 1950, Journal of the American Medical Association.

[63]  Sajjad Ahmad,et al.  The AMA proposal to mandate nicotine reduction in cigarettes: a simulation of the population health impacts. , 2005, Preventive medicine.

[64]  C. Lerman,et al.  Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment , 2008, The Pharmacogenomics Journal.

[65]  T. Fukuda,et al.  Cost-Utility Analysis of Varenicline, an Oral Smoking-Cessation Drug, in Japan , 2012, PharmacoEconomics.

[66]  P. Mabry,et al.  Boosting population quits through evidence-based cessation treatment and policy. , 2010, American journal of preventive medicine.

[67]  K. Thavorn,et al.  A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand , 2008, Tobacco Control.